Literature DB >> 2942238

Immunomodulatory and therapeutic properties of bestatin in mice.

J E Talmadge, B F Lenz, R Pennington, C Long, H Phillips, M Schneider, H Tribble.   

Abstract

In this report, we describe the immunomodulatory properties and therapeutic efficacy of bestatin. Macrophage activation, but not natural killer cell augmentation, was observed both in vitro and in vivo. Immunostimulation of T-cell activity was observed in assays of allogeneic mixed lymphocyte response, but cytotoxic effector cells did not develop after an allogeneic mixed lymphocyte-tumor cell culture. Bestatin also had T-cell adjuvant activity when it was admixed with a suboptimal vaccine composed of irradiated tumor cells. We observed significant therapeutic activity against preexisting experimental and spontaneous metastases when bestatin was administered at high doses per animal for 4 weeks.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942238

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Immunomodulatory and therapeutic properties of FK-565 in mice.

Authors:  J E Talmadge; B Lenz; M Schneider; H Phillips; C Long
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases.

Authors:  F Abe; G Alvord; M Koyama; A Matsuda; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery.

Authors:  Timothy E Andrews; Dan Wang; Daniel A Harki
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

4.  Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.

Authors:  M Kawalec; T Skórski; J Kawiak
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

5.  Enzymes and inhibitors in leu-enkephalin in metabolism in human plasma.

Authors:  F Bolacchi; M Marini; A Urbani; L G Roda
Journal:  Neurochem Res       Date:  1995-09       Impact factor: 3.996

6.  Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1.

Authors:  S Sasaki; J Fukushima; K Hamajima; N Ishii; T Tsuji; K Q Xin; H Mohri; K Okuda
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

7.  Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13.

Authors:  H Fujii; M Nakajima; I Saiki; J Yoneda; I Azuma; T Tsuruo
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

8.  Stromal aminopeptidase N expression: correlation with angiogenesis in non-small-cell lung cancer.

Authors:  Shinya Ito; Ryo Miyahara; Rei Takahashi; Shinjiro Nagai; Kazumasa Takenaka; Hiromi Wada; Fumihiro Tanaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-11-12

9.  A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.

Authors:  C M L van Herpen; F A L M Eskens; M de Jonge; I Desar; L Hooftman; E A Bone; J N H Timmer-Bonte; J Verweij
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

10.  Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice.

Authors:  F Abe; A Matsuda; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.